Current management of deep vein thrombosis;Aktuelles Management der tiefen Venenthrombose

Medizinische Welt

Volumn 49, Issue 4 A, 1998, Pages 194-214

  Bauersachs, R M ^a   Lindhoff Last, Edelgard ^a   Wolff, U ^a   Ehrly, A M ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Anticoagulants; Heparin induced; Thrombocytopenia; Thrombophilia; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ANTICOAGULATION; DEEP VEIN THROMBOSIS; DISEASE CONTROL; DRUG SAFETY; GERMANY; HUMAN; MOBILIZATION; OCCULT CANCER; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; THROMBOCYTOPENIA; TREATMENT PLANNING;

EID: 0031969170     PISSN: 00258512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (260)

1. Albada J, Nieuwenhuis HK. Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation 1989; 80: 935-40.
2. Alhenc-Gelas M. Jestin-Le Guernic C, Vitoux JF, Kher, Aiach M. Fiessinger JN. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group. Thromb Haemost 1994; 71:698-702.
3. Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briet E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341: 134-8.
4. Alpert JS, Dalen JE. Epidemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis 1994; 36: 417-22.
5. Amundsen T, Ueland PM, Waage A. Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromb Vasc Biol 1995: 9: 1321-3.
6. Anderson DR, Lensing AW, Wells PS, Levine MM, Weitz JI, Hirsh J. Limitations of impedance plethysmography in the diagnosis of clinically suspected deepvein thrombosis. Ann Intern Med 1993: 118: 25-30.
7. Anderson FA Jr. Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Int Med 1991: 151: 933-8.
8. Anonymous. International Committee for Standardization in Haematology. International Committee on Thrombosis and Haemostasis: ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost 1985: 53: 155-6.
9. Anonymous. Guidelines on the investigation and management of thrombophilia. The British Committee for Standards in Haematology. J Clin Pathol 1990: 43: 703-9.
10. Ansell JE, Patel N, Ostrovsky D, Nozzolillo E, Peterson AM, Fish L. Long-term patient self-management of oral anticoagulation. Arch Int Med 1995: 155: 2185-9.
11. Arnesen H, Hoiseth A, Ly B. Streptokinase or heparin in the treatment of deep vein thrombosis: Follow-up results of a prospective study. Acta Med Scand 1982: 211: 65-8.
12. Asherson RA, Harris NE, Hughes GRV. Complications of oral contraceptives and antiphospholipd antibodies. Arthritis Rheum 1987: 30: 575-6.
13. Bacher P, Welzel D, Iqbal O. Hoppen-steadt D, Callas D, Walenga JM, Fareed J. The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model. Thromb Res 1992: 66: 151-8.
14. Baldridge ED, Martin MA, Welling RE. Clinical significance of free-floating venous thrombi. Journal of Vascular Surgery 1990: 11: 62-7.
15. Barbour L, Kick S, Steiner J, LoVerde M, Heddleston L, Lear J, Baron A, Barton P. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994: 170: 862-9.
16. Barnes RW, Krapf T, Hoak JC. Erroneous clinical diagnosis of leg vein thrombosis in women on oral contraceptives. Obstet Gynecol 1978: 51: 556-8.
17. Barritt DW, Jordan SC. Anticoagulant drags in the treatment of pulmonary embolism. A controlled trial. Lancet 1960: i: 1309-12.
18. Bauersachs R, Lindhoff-Last E, Ehrly AM. Kuhl H. Die Bedeutung der hereditaren Thrombophilie für das Thromboserisiko unter der oralen Kontrazeption. Zentralbl Gynakol 1996: 118: 262-70.
19. Bauersachs R, Lindhoff-Last E, Kuhl H, Ehrly AM. Thromboserisiko bei oralen Kontrazeptiva: Stellenwert eines Thrombophilie-Screenings. VASA 1996; 25: 209-20.
20. Baxter GM. Peripheral venous imaging using color flow doppler. Med Care 1993; 17-24.
21. Becker DM, Philbrick JT, Selby JB. Inferior vena cava filters. Indications, safety, effectiveness.. Arch Int Med 1992; 152: 1985-9.
22. Ben Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost 1989; 61: 50-4.
23. Bendetowicz AV, Beguin S, Caplain H, Hemker HC. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin - a three way cross over study in human volunteers. Thromb Haemost 1994; 71:305-13.
24. Bergqvist D, Jaroszewski H. Deep vein thrombosis in patients with superficial thrombophlebitis of the leg. BMJ 1986; 292: 658-9.
25. Bertina RM. Laboratory diagnosis of resistance to activated Protein C (APC-resistance). Thromb Hemost 1997; 78: 478-82.
26. Biland L, Zemp E, Widmer LK. Zur Epidemiologie der venösen Thromboembolic. Internist 1987; 28: 285-90.
27. Blättler W. Ambulatory care for ambulant patients with deep vein thrombosis. Journal des Maladies Vasculaires 1991; 16: 137-4.
28. Blättler W, Bulling B, Hertel T, Rabe E. Leitlinien zur Diagnostik und Therapie der Thrombophlebitis superficialis. Phlebologie 1997; 25: 197-8.
29. Bloemenkamp KWM, Rosendaal FR. Heimerhorst FM, Buller HR. Vanden-broucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6.
30. Bounameaux H, de Moerloose P, Perrier A, Reber G. Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: an overview. Thromb Haemost 1994: 71: 1-6.
31. Bounameaux H, de Moerloose P, Sarasin FP. Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs. Blood Coagul Fibrinolysiss 1996; 7: 507-14.
32. Brandjes DP, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 1485-9.
33. Brandjes DPM. Büller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, ten Cate JW. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997: 349: 759-62.
34. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995: 74: 1185-9.
35. Brattstrom L, Tengborn L, Lagerstedt C, Israelsson B, Hultberg B. Plasma homocysteine in venous thromboembolism. Haemostasis 1991; 21: 51-7.
36. Breddin HK. Treatment of deep vein thrombosis: is thrombosis regression a desirable endpoint. Seminars in Thromb Hemost 1997; 23: 179-83.
37. Briet E, van der Meer FJ, Rosendaal FR, Houwing Duistermaat JJ, van Houwelingen HC. The family history and inherited thrombophilia. Br J Haematol 1994; 87: 348-52.
38. Brill Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993: 119: 104-9.
39. British Committee for Standards in Haematology. Haemostasis and Thrombosis Task Force. Guidelines on oral anticoagulation: second edition. British Society for Haematolosy. J Clin Pathol 1990; 43: 177-83.
40. Brockmans AW, Bertina RM, Loeliger EA, Hofmann V, Klingemann HG. Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemostas 1983: 49: 251.
41. Caspary L, Creutzig A, Alexander K, Wie häufig ist die Lysetherapie ber tiefer Becken-Bein-Venenthrombose indiziert. Mod Klin 1995; 90: 618-22.
42. Cattaneo M, Martinelli I, Mannucci PM. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 335: 974-5.
43. Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49: 171-178.
44. Cogo A, Lensing WA, Koopman MW, Piovella F, Wells P, Villata S, Siragusa S, Buller HR. Turpie GG, Prandoni P. Compression ultrasound for the diagnostic management of clinically suspected deepvein thrombosis. Thromb Haemost 1995: 1098 A.
45. Common HH, Seaman AJ, Rosch J, Porter JM, Dotter CT. Deep vein thrombosis treated with streptokinase or heparin. Follow-up of a randomized study. Angiology 1976; 27: 645-54.
46. Coon WW, Willis PW, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation 1973; 48: 839-46.
47. Cornuz J, Pearson SD, Creager MA, Cook EF, Goldman L. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Int Med 1996; 125: 785-9.
48. Creutzig A. Phlebothrombose. In: Gefäß krankheiten. Alexander K. (eds). München. Wien. Baltimore: Urban & Schwarzenberg 1992; 665-87.
49. Crochet DP, Stora O, Ferry D, Grossetete R, Leurent B, Brunel P, Nguyen JM. Vena Tech-LGM filter: long-term results of a prospective study. Radiology 1993; 188: 857-60.
50. Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Int Med 1991; 151: 333-7.
51. Dahlbäck B. Resistance to activated Protein C by the Factor V R506Q Mutation is a common risk factor for venous thromboembolism. Thromb Hemostas 1997; 78: 483-8.
52. Dahlman T. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168: 1265-7.
53. Daly H. Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
54. Daly E, Vessey MP, Painter R. Hawkins MM. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet 1996; 348: 1027.
55. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531-4.
56. de Valk HW, Banga JD, Wester JW, Brouwer CB, van Hessen MW. Meuwissen OJ, Hart HC, Sixma JJ, Nieuwenhuis HK. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Int Med 1995; 123: 1-9.
57. den Heijer M, Blom HJ, Gerrits WB, Rosendaal FR, Haak HL, Wijermans PW, Bos GM. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis. Lancet 1995; 345: 882-5.
58. den Heijer M, Koster T, Blom HJ, Bos GMJ, Briet E, Reitsma PH. Vandenbrouke JP. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
59. Diehm C, Spengel FA. Thrombophlebitis (oberflächliche Venenentzündung). In: Rationelle Diagnostik und Therapie in der Inneren Medizin. M. Classen, R. Dierkes-mann: H. Heimpel: J. R. Kalden: K.-M. Koch; J. Meyer: F. A. Spengel; R. Ziegler (eds). chap. E13. München, Wien. Baltimore: Urban & Schwarzenberg 1997; 1-4.
60. Diehm C, Stammler F, Amendt K. Die tiefe Venenthrombose. Dt Ärztebl 1997; 94: 253-63.
61. Duckert F, Muller G, Nyman D, Benz A, Prisender S, Madar G, Da Silva MA, Widmer LK, Schmitt HE. Treatment of deep vein thrombosis with streptokinase. Br Med J 1975; 1: 479-81.
62. Ehringer H, Minar E. Die Therapie der akuten Becken-Bein-Venenthrombose. Internist 1987; 28: 317-35.
63. Eichlisberger R, Frauchiger B, Widmer MT, Widmer LK. Jäger K. Spatfolgen der tiefen Beinvenenthrombose: ein 13-Jahre-Follow-up von 223 Patienten. VASA 1994; 23: 234-43.
64. Elliot MS, Immelman EJ, Jeffery P, Benatar SR, Funston MR, Smith JA, Shepstone BJ, Ferguson AD, Jacobs P, Walker W, Louw JH. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. Br J Surg 1979; 66: 834-8.
65. Engesser L. Thrombophilia - Disorders of blood coagulation and fibrinolysis. In: Thesis: University Leiden 1988.
66. Eriksson BI, Ekman S, Kälebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin. CGP 39393. Lancet 1996; 347: 635-9.
67. Eriksson B1. Wille-Jorgensen P, Kälebo P, Mouret P, Rosencher N, Bösch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P. A comparison of recombinant hirudin with a low-molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-35.
68. Falcon CR, Cattaneo M, Panzeri O, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080-3.
69. Fermo I, Vigano D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Int Med 1995; 123: 747-53.
70. Fiessinger JN, Charbonnier BA, Sixma JJ, Wenzel E, d'Azemar P, Sagnard L. For the FRAXODI Group. Comparison of a once daily with a twice daily subcutaneous nadroparin calcium regimen in the treatment of deep vein thrombosis. Thromb Haemost 1997: Suppl: 388.
71. Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, Soderberg K. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996: 76: 195-6.
72. Finazzi G, Barbui T. Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III. protein C and protein S. Thromb Haemost 1994; 71: 15-8.
73. Fobbe F, Dietzel M, Korth R, Felsenberg D, Bender S, Hamed M, Laass C. Sorensen R. Gunther vena caval filter: results of long-term follow-up. AJR 1988; 151: 1031-4.
74. Franzeck UK, Schalch I, Bollinger A. On the relationship between changes in the deep venis evaluated by duplex sonography and the postthrombotic syndrome 12 years after deep vein thrombosis. Thromb Haemost 1997; 77: 1109-12.
75. Franzeck UK, Schalch I, Jager K, Grimm J, Schnieder E, Bollinger A. Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis (Zurich study). Circulation 1996; 93: 74-9.
76. Fürst G, Kuhn F-P, Trappe RT, Modder U, Diagnostik der tiefen Beinvenenthrombose. Fortschr Römgenstr 1990; 152: 151-8.
77. Geerts W, Code K, Jay R. Chen, Szalai J. A prospective study of venous thromboembolism after major trauma. N Engl J Med 1994; 331: 1601-6.
78. Geisinger MA, Zelch MG, Risius B. Recurrent pulmonary embolism after Greenfield filter placement. Radioloay 1987; 165: 383-4.
79. Gillis S, Shushan A, Eldor A. Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy. Int J Gynaecol Obstet 1992; 39: 297-301.
80. Ginsberg J. Management of venous thromboembolism. N Engl J Med 1996; 335: 1816-28.
81. Ginsberg J, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R, Coates G, Webber C. Heparin effect on bone density. Thromb Haemost 1990; 64: 286-9.
82. Ginsberg JS, Brill Edwards P, Burrows RF, Bona R, Prandoni P, Buller HR, Lensing A. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 1992; 67: 519-20.
83. Ginsberg JS, Wells PS, Hirsh J, Panju AA, Patel MA, Malone DE, McGinnis J, Stevens P. Brill Edwards P. Reevaluation of the sensitivity of impedance plethysmography for the detection of proximal deep vein thrombosis. Arch Intern Med 1994; 154: 1930-3.
84. Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston H, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-9.
85. Ginsberg JS, Kearon C, Douketis J, Turpie AGG, Brill-Edwards P, Stevens P, Oanju A, Patel A, Crowther M, Andrew M, Massicotte P, Hirsh J, Weitz JI. The use of d-dimer testing and impedance plethysmographic examination in patients with clinical indications of deep vein thrombosis. Arch Int Med 1997; 157: 1077-81.
86. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997-1002.
87. Goldberg RJ, Seneff M, Gore JM, Anderson FA Jr, Greene HL, Wheeler HB, Dalen JE. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Int Med 1987; 147: 251-3.
88. Goldhaber S. Z. Morpurgo M. Diagnosis, treatment, and prevention of pulmonary embolism. Report of the WHO/International Society and Federation of Cardiology Task Force. JAMA 1992; 268: 1727-33.
89. Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH. Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am J Med 1984; 76: 393-7.
90. Greinacher A. Neue antithrombotische Medikamente. Internist 1997; 38: 680-7.
91. Griffin M, Stanson A, Brown M, Hauser M, O'Fallon W, Anderson H, Kazmier F. Melton LJ 3. Deep venous thrombosis and pulmonary embolism. Risk of subsequent malignant neoplasms. Arch Int Med 1987; 147: 1907-11.
92. Habscheid W, Hohmann M, Wilhelm T, Epping J. Real-time ultrasound in the diagnosis of acute deep venous thrombosis of the lower extremity. Angiology 1990; 41: 599-608.
93. Hafner CO, Cranley JJ, Krause RJ, Strasser ES. A method of managing superficial thrombophlebitis. Surgery 1964; 55: 201-6.
94. Harenberg J, Leber G. Dempfle CE, Heene DL, Zimmermann R, Kubler W. Long term anticoagulation with low molecular weight heparin in outpatients with side effects on oral anticoagulants. Nouv Rev Fr Hematol 1989; 31: 363-9.
95. Harenberg J, Huck K, Bratsch H, Stehle G, Dempfle CE, Mall K, Blauth M, Usadel KH, Heene DL. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemostasis 1990; 20 Suppl 1: 205-19.
96. Harenberg J, Schmitz-Huebner U, Breddin KH, Haas S, Heinrich F, Heinrichs Ch, Kienast J, Roebruck P, Theiss W, Wenzel E. Treatment of deep vein thrombosis with low-molecular-weight heparins: A consensus statement of the Gesellschaft für Thrombose- und Hämostaseforschung (GTH). Sem Thromb Haemost 1997; 23: 91-6.
97. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Int Med 1997: 126: 133.
98. Hasenkam JM, Knudse LN, Kimose HH, Gronnesby H:, Attermann J, Andersen NT, Pilegaard HK. Practicability of patient self-testing of oral anticoagulant therapy by the international normalized ratio (INR) using a portable whole blood monitor. A pilot investigation. Thromb Res 1997; 85: 77-8.
99. Heijboer H, Brandjes DP, Buller HR, Sturk A. ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-6.
100. Heijboer H, Cogo A, Buller HR, Prandoni P. ten Cate JW. Detection of deep vein thrombosis with impedance plethysmography and real-time compression ultra-sonography in hospitalized patients. Arch Intern Med 1992; 152: 1901-3.
101. Heijboer H, Buller HR, Lensing AW, Turpie AG, Colly LP, ten Gate JW. A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med 1993; 329: 1365-9.
102. Heinrich F, Primäre Thromboseprophylaxe in der inneren Medizin. In: Thromboembolie-Prophylaxe in der inneren und operativen Medizin. V. Hach-Wunderle; S. Haas (eds). Berlin Heidelberg: Springer Verlag 1997; 49-62.
103. Hillar A, Zoller B, Sevensson PJ, Dahlbäck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997; 78: 990-2.
104. Hirsch DR, Lee TH, Morrison RB, Carlson W, Goldbaber SZ. Shortened hospitalization by means of adjusted-dose subcutaneous heparin for deep venous thrombosis. Am Heart J 1996; 131: 276-8.
105. Hirsch DR, Mikkola KM, Marks PW, Fox EA, Dorfman DM, Ewenstem BW, Goldhaber SZ. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J 1996; 131: 1145.
106. Hirsh J. Drug therapy - oral anticoagulant drugs. N Engl J Med 1990; 324: 1865-75.
107. Hirsh J. Substandard monitoring of warfarin in North America. Time for change. Arch Intern Med 1992; 152: 257-8.
108. Hirsh J, Piovella F, Pini M, Congenital antithrombin III deficiency. Incidence and clinical features. Am J Med 1989; 87, 34S-38S.
109. Holmström M, Lindmarker P, Granquvist S, Johnsson H, Lockner D. A 6-month venographic follow-up in 164 patients, with acute deep vein thrombosis. Thromb Haemost 1997; 77: 803-7.
110. Hommes DW, Bura A, Mazzolai L. Buller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Int Med 1992; 116: 279-84.
111. Hull RD. Anticoagulant treatment. Int Angio 1995: 14: 32-44.
112. Hull RD, Delmore T, Genton E, Hirsh J, Gent M, Sackett DL, McLoughlin D., Armstrong P. Warfarin sodium versus low-dose heparin in the long term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-8.
113. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L et al., Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-14.
114. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR. et al. Subcutaneous low-molecular-weight heparin compared with intravenous standard heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
115. Hull RD, Raskob GE, Rosenbloom D, Lemaire J, Pineo GF, Baylis B, Ginsberg JS, Panju AA, Brill-Edwards P, Brant R. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Int Med 1992; 152: 1589-95.
116. Hunt BJ, Doughty HA, Majumdar G, Copplestone A, Kerslake S, Buchanan N, Hughes G, Khamashta M Thromhoprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thrombosis & Haemostasis 1997; 77: 39-43.
117. Jamieson SW, Auger WR, Fedullo PF, Channick RN, Kriett JM, Tarazi RY, Moser KM. Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period. J Thorac Cardiovasc Sura 1993: 106: 116-26.
118. Jick H, Jick SS, Gurewich V, Myeres MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
119. Jick H, Derby LE, Myres MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-3.
120. Jorgensen JO, Hanel KC, Morgan AM, Hunt JM. The incidence of deep venous thrombosis in patients with superficial thrombophlebitis of the lower limbs. J Vasc Surg 1993; 18: 70-3.
121. Kakkar VV, Dalteparin prevention of recurrent DVT - a study versus Warfarin. Haemost 1994; 24 (Suppl.):45a.
122. Kakkar VV, Lawrence D. Hemodynamic and clinical assessment after therapy for acute deeep vein thrombosis. Am J Surg 1985: 150 Suppl: 54-63.
123. Kakkar VV, Flanc C, Howe CT, O'Shea M, Flute PT. Treatment of deep vein thrombosis. A trial of heparin. streptokinase, and arvin. Br Med J 1969; 1: 806-10.
124. Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg. Is there a ≫high risk≪ group? Am J Surg 1970; 120: 527-30.
125. Kasprzak P, Noppeney T, Raithel D. Früh- und Langzeitergebnisse der venosen Thrombektomie bei tiefer Bein- und Beckenvenenthrombose. VASA 1987: suppl 20: 150-2.
126. Kearon C, Hirsh J. Management of anticoagulation before and after elective- surgery. N Engl J Med 1997; 336: 1506-11.
127. Khamashta MA, Cuadrado MJ, Muijc F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the anti-phospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.
128. Kierkegaard A. Incidence of acute deep vein thrombosis in two districts. Acta Chir Scand 1980; 146: 267-9
129. Kierkegaard A. Incidence and diagnosis of deep vein thrombosis associated with pregnancy. Acta Obstet Gynecol Scand 1983; 62: 239-44.
130. Kirchmaier CM. Lindhoff Last E. Rubesam D. Scharrer I, Vigh Z. Mosch G, Wolf H. Breddin HK. Regression of deep vein thrombosis by i.v. administration of a low molecular weight heparin - results of a pilot study. Thromb Res 1994; 73: 337-48.
131. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
132. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM. van der Meer J, Callus AS, Simonneau G, Chesterman CH, Prins MH, Bossuy PMM, De Haes H, Van den Belt AGM, Sagnard L, D'Azemar P, Buller H, For the Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl Med 1996; 334: 682-7.
133. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thromhophilia Study. Lancet 1993; 342: 1503-6.
134. Koster T, Rosendaal FR, Briet E, van der Meer FJ, Colly LP, Trienekens PH, Poort SR, Reitsma PH, Vandenbroucke JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756-61.
135. Koster T, Blann AD, Briet E, Vanden-broucke JP, Rosendaal FR. Role of clotting factor VIII and effect of von Willebrand factor on occurrence of deep-vein thrombosis . Lancet 1995; 345: 152-5.
136. Lagerstedt CI, Olsson C-G, Fagher BO, Öqvist BW, Albrechtson U. Need for longterm anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2: 515-8.
137. Landefeld C, Andersen P, Guideline-based consultation to prevent anticoagulant-related bleeding. A randomized, controlled trial in a teaching hospital. Ann Int Med 1992; 116: 829-33.
138. Landefeld CS, Goldman L, Major bleeding in outpatients treated with warfarin, incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-5.
139. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlback B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: Part 2. Thromb Haemost 1996; 76: 824-34.
140. Lechner K., Risikofaktoren der Venen-thrombose. In: Postoperative Thromboembolie-Prophylaxe aus aktueller Sicht. H. Tscherne: E. Deutsch (eds). Stuttgart. New York: Thieme 1981; 7-17.
141. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994; 309: 299-304.
142. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995; 155: 601-7.
143. LeSiege CJ, McKean SC, Persson AV. Importance of valvular incompetence after acute deep venous thrombosis. J Cardiovasc Surg Torino 1992; 33: 710-4.
144. Leu HJ. Histologische Altersbestimmung von arteriellen und venösen Thromben und Emboli. VASA 1973; 2: 265-74.
145. Leu HJ. Gefäßwandbedingte Einflusse auf Entstehung und Verlauf der Venenthrombose. VASA 1975; 4: 5-15.
146. Levine M, Gent M, Hirsh J, Leclerc J, Andersen D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, Geerts W, Kassts J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81.
147. Levine MN, Hirsh J, Landefeld S, Raskob G. Hemorrhagic complications of anticoagulant treatment. Chest 1992; 102: 352S-63S.
148. Levine MN, Goldhaber SZ, Califf RM, Gore JM, Hirsh J. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 1992; 102: 364S-73S.
149. Levine MN, Hirsh J, Gent M, Turpie A, Cruickshank M, Weitz J, Andersen D, Johnson M. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Int Med 1994; 154: 49-56.
150. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-90.
151. Lopaciuk S. For The Polish Venous Thrombosis Study Group. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemostas 1997; Suppl: 767.
152. Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Ciesielski L, Bielawiec M, Glowinski S, Czestochowska E. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992; 68: 14-8.
153. Ludlam C. A. Bennett B, Fox KA, Lowe GD, Reid AW, Guidelines for the use of thrombolytic therapy. Haemostasia and Thrombosis Task Force of the British Committee for Standards in Haematology. Blood Coagul Fibrinolysis 1995; 6: 273-8.
154. Luomanmaki K, Grankvist S, Hallert C, Jauro I, Ketola K, Kim HC, Kiviniemi H, Koskivirta H, Sorskog L, Vilkko P. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. J Int Med 1996; 240: 85-9.
155. Lutter KS, Kerr TM, Roedersheimer LL, Lohr JM, Sampson MU. Cranley JJ, Superficial thrombophlebitis diagnosed by duplex scanning. Surgery 1991; 110: 42-6.
156. Magnani H, Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70: 554-6.
157. Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease - Critical Evaluation of laboratory investigation. Thromb Haemost 1992; 68: 7-13.
158. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Color. Cancer Control Study. N Engl J Med 1993; 328: 1365-71.
159. Markel, Manzo R, Bergelin R, Strandness DE J. Pattern and distribution of thrombin in acute venous thrombosis. Arch Surg 1992; 127: 305.
160. Markel A, Manzo RA, Strandness Jr. DE. The potential role of thrombolytic therapy in venous thrombosis. Arch Intern Med 1992; 152: 1265-7.
161. Martin M. PHLEKO-PHLEFI-Studien. VASA 1997; Suppl 49: 5-37.
162. Mattos MA, Londrey GL, Leutz DW, Hodgson KJ, Ramsey DE, Barkmeier LD, Stauffer ES, Spadone DP, Sumner DS, Color-flow duplex scanning for the surveillance and diagnosis of acute deep venous thrombosis. J Vasc Surg 1992; 15: 366-75.
163. McColl MD, Ramsay JE, Tait RC, Walkee ID, McCall F, Conkie JA, Carty MJ, Greer IA. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78 1183-8.
164. Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemberton KD, Nicolaides KH, Barrett JJ, Kakkar VV. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68: 652-6.
165. Meyer G, Brenot F, Pacouret G. Simonneau G. Gillet Juvin K. Charbonnier B, Sors H, Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. Thromb Haemostas 1995; 74: 1432-1435.
166. Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-6.
167. Millward SF, Bormanis J, Burbridge BE, Markman SJ, Peterson RA. Preliminary clinical experience with the Gunther temporary inferior vena cava filter. Journal of Vascular & Interventional Radiology 1994; 5: 863-8.
168. Milne AA, Stonebridge PA, Bradbury AW, Ruckley CV. Venous function and clinical outcome following deep vein thrombosis. Br J Surg 1994; 81: 847-9.
169. Monreal M, Vinas E, Monreal L, Lavin S, Lafoz E, Angles AM, Heparin-related osteoporosis in rats. A comparative study between unfractioned heparin and a lowmolecular-weight heparin. Haemostasis 1990; 20: 204.
170. Monreal M, Lafoz E, Salvador R. Roncales J, Navarro A. Adverse effects of three different forms of heparin therapy: thrombocytopenia. increased transaminases, and hyperkalaemia. Eur J Clin Pharmacoly 1989; 37: 415.
171. Monreal M, Lafoz E, Ruiz J, Valls R, Alastrue A. Upper-extremity deep venous thrombosis and pulmonary embolism. A prospective study. Chest 1991; 99: 280-3.
172. Monreal M, Lafoz E, Casals A, Inaraja L, Montserrat E, Callejas JM, Martorell A. Occult cancer in patients with deep vein thrombosis: a systematic approach. Cancer 1991; 67: 541-5.
173. Monreal M, Casals A, Boix J, Olazabal A, Montserrat E, Mundo MR. Occult cancer in patients with acute pulmonary embolism. A prospective study. Chest 1993; 103: 816-9.
174. Monreal M, Lafoz E, Olive A, del Rio L. Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
175. Mostbeck GH. Ultrasound ≫screening examination≪ of the abdomen: of value or senseless? Ultraschall Med 1996; 17: 175-8.
176. Mussurakis S. Compression US in isolated calf venous thrombosis. Radiology 1991; 181: 351-3.
177. Nicolaides AN, Bergqvist D. Hull R Prevention of venous thromboembolism. International Consensus Statement (guideline according to scientific evidence). Int Angiol 1997; 16: 3-38.
178. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Int Med 1992: 232: 155-6.
179. Nowak G, Bucha A. Quantitative determination of hirudin in blood and body fluids. Sem Thromb Hemost 1996; 22: 197-202.
180. Nylander G, Olivecrona H, The phlebographic pattern of acute leg thrombosis within a defined urban population. Acta Chir Scand 1976; 142: 505-11.
181. Odegard OR, Abildgaard U. Antithrombin III: critical review of assay methods. Haemostasts 1978; 7: 127-32.
182. Ohgi S, Kanaoka Y, Mori T. Objective evaluation of compression therapy for deep vein thrombosis by ambulatory straingauae plethysmoaraphy. Phlebology 1994; 9: 28-31.
183. O'Meara JJ 3rd, McNutt RA, Evans AT, Moore SW, Downs SM. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med 1994; 330: 1864-9.
184. O'Shaughnessy MA, Fitzgerald DE. Natural history of proximal deep vein thrombosis assessed by duplex ultrasound. Int Angiol 1997; 16: 45-9.
185. Ott P, Eldrup E, Oxholm P, Vestergard A. Knudsen JB Streptokinase therapy in the routine management of deep venous thrombosis in the lower extremities. A retrospective study of phlebographic results and therapeutic complications. Acta-Med-Scand 1986; 219: 295-300.
186. Pabinger I, Schneider B, Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost 1994; 71: 548-52.
187. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G. Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8.
188. Partsch H. Investigations on the pathogenesis of venous leg ulcers. Acta Chir Scand Suppl 1988; 544: 25-9.
189. Partsch H. Diagnose und Therapie der tiefen Venenthrombose. VASA 1996; Suppl 46: 1-53.
190. Partsch H, Oburger K, Mostbeck A, Konig B, Kühn H. Frequency of pulmonary embolism in ambulant patients with pelvic vein thrombosis: A prospective study J Vasc Surg 1992; 16: 715-22.
191. Paschalidis M, Theiss W, Schaub F, Heinz, M. Langzeitverlauf nach tiefer Schulter-gurtelvenenthrombose. VASA 1997: Suppl 50: 37.
192. Pearson S, Lee T, McCabe-Hassan, Dorsey J, Goldhaber S. A critical pathway to treat proximal lower-extremity deep vein thrombosis. Am J Med 1996; 100: 283.
193. Perez Gutthann S. Garcia Rodriguez LA, Castellsague J, Oliart AD. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. Br Med J 1997; 314: 796-800.
194. Piccioli A, Prandoni P, Ewenstein B, Goldhaber S. Cancer and venous thromboembolism. Am Heart J 1996; 132: 850.
195. Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, Taeliaferri A, Dettori AG. Low molecular weight heparin versus warfarin in the presention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72: 191.
196. Plate G, Einarsson E, Ohlin P, Jensen R, Ovarfordt P, Eklof B. Thrombectomy with temporary arteriovenous fistula: the treatmom of choice in acute iliofemoral venous thrombosis. J Vasc Surg 1984; 1: 867.
197. Poort S, Rosendaal F, Reitsma P, Bertina R. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3670-98.
198. Powers PJ, Gent M, Jay RM, Julian DH, Turpie AG, Levine M, Hirsh J. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thrombocmbolism after surgery for fractured hip. Arch Intern Med 1989; 149: 771-4.
199. Prandoni P. Antithrombotic strategies in patients with Cancer. Thromb Haemostas 1997; 78: 141-144.
200. Prandoni P. Lensing AWA. Büller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW. Deep-vein thrombosis and the incidence of subsequent cancer. N Engl J Med 1992; 327: 1128-32.
201. Prandoni P, Lensing AW, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW. Comparison of subcutaneous lowmolecular-ueight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-5.
202. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta A, Cattelan AM, Polistena P, Bernardi E, Prins MA. The longterm clinical course of acute deep venous thrombosis. Annals of Internal Medicine 1996; 125: 1-7.
203. Prandoni P, Polistena P, Bernardi E, Cogo A, Casara D, Verlato F, Angelini F, Simioni P, Signorini GP, Benedetti L, Girolami A. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Int Med 1997: 157: 56-7.
204. Prins MH, Hettiarachchi RJK, Lensing AWA, Hirsh J. Newly diagnosed malignancy in patients with thromboembolism. Search or wait and see. Thromb Hemost 1997; 78: 121-5.
205. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a ≫standard care≪ nomogram. A randomized controlled trial. Ann Int Med 1993; 119: 874-81.
206. Raskob G, Hull R, Pineo G, Valentine K, Barnt R. Relation between the time to achieve a lower limit of the APTT therapeutic range and recurrent venous thromhembolism during heparin treatment for deep-vein thrombosis. Thromb Haemost 1997: Suppl: 387.
207. Ridker P, Miletich J, Stampfer M, Goldhaber S, Lindpaintner, Hennekens C. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2.
208. Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Int Med 1997; 126: 523-8.
209. Rieger H, Protokoll über eine Diskussion uber die Frage, inwieweit eine klinische Vergleichsstudie: ≫Systemische Thrombolyse versus Thrombektomie bei tiefer Bein-/Beckeneventhrombose≪ sinnvoll und durchfuhrbar ist. Mitteilungen der Deutschen Gesellschaft für Angioloeie 1995: 52-5.
210. Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975; 292: 146-51.
211. Rosenberg RD, Bauer KA. Thrombosis in inherited deficiencies of antithrombin. protein C. and protein S. Hum-Pathol 1987: 18: 253-62.
212. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997; 78: 7-12.
213. Rosfors S, Eriksson M, Leijd B, Nordström E. A prospective follow-up study of acute deep venous thrombosis using colour duplex ultrasound, phlebography and venous occlusion plethssmography. Int Angiol 1997; 16: 39-14.
214. Rutherford SE, Phelan JP. Deep venous thrombosis and pulmonary embolism in pregnancy. Obstet Gynecol Clin North Am 1991; 18: 345-70.
215. Sallah S, Thomas DP, Roberts HR. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: Infrequent complications of anticoagulant treatment. Thromb Haemost 1997; 78: 785-90.
216. Sarasin FP, Bounameaux H. Duration of oral anticoagulant therapy after proximal deep vein thrombosis: a decision analysis. Thromb Haemost 1994; 71: 286-91.
217. Schmutzler R. Klinik der thrombolytischen Behandlung. Internist 1969; 10: 21-9.
218. Schneider PA, Geissbuhler P, Piguet JC, Bounameaux H, Follow-up after partial interruption of the vena cava with the Gunther filter. Cardiovasc Intervent Radiol 1990; 13: 378.
219. Schulman, S., Duration of anticoagulant therapy for venous thrombosis. N Engl J Med 1995; 333: 1289
220. Schulman S. Optimal duration of oral anticoagulant therapy in venous thromboembolism. Thromb Haemo 1997; 78: 693-8.
221. Schulman S, Rhedin A.-S. Lindmarker P, Carlsson A, Larfars G., Nicol P, Loogna E, Svensson E. Ljungberg B, Walter H. For the Duration of Anticoagulation Trial Study Group. Comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. New Engl J Med 1995: 332: 1661-5.
222. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lartars G, Leijd B. Linder O. Loogna E. The Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode: of venous thromboembolism in venous thromboembolism. N Engl J Med 1997; 336: 393-8.
223. Schulman S, Stigendal L, Jansson JH. Brohult J. Haemorrhagic and thromboembolic complications versus intensity of treatment of venous thromboembolism with oral anticoagulants. Acta Med Scand 1988; 224: 425-30.
224. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin. antibodies in a healthy population. Aust NZJ Med 1990; 20: 231-6.
225. Simioni P, Prandoni P, Burlina A,Tormene D, Sardella C, Ferrari V, Benedetti L, Girolami A. Hyperhomocysteinemia and deep-vein thrombosis. A case-control study. Thromb Haemost 1996; 76: 883-6.
226. Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A. The risk of recurrent venous thrombembolism in patients with an Arg506->Gln mutation of the gene for Factor V (Factor V Leiden). N Engl J Med 1997; 336: 399-403.
227. Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, Silsiguen M, Combe S. Subcutaneous low-molecularweight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis Arch Intern Med 1993; 153: 1541-6.
228. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban J-P. Azarian R, Laurent M, Hirsch J-L, Ferrari E, Bosson J-L, Mottier D, Beau B. For the THESEE Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-9.
229. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 267-9.
230. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD. on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation oral contraceptives and risk of venous thromboembolic disorders' an international case-control study. Br Med J 1996; 312: 83-8.
231. Stiegler H, Mosavi S, Rotter G, Weichen-hain B, v. Kooten HJ, Standl R. Spontanverlauf der flottierenden Beinvenenthrombose unter konservativer Behandlung. VASA 1993; Suppl. 43: 104.
232. Suandness DE Jr. Langlois Y, Cramer M, Randlett A, Thiele BL. Long-term sequelae of acute venous thrombosis. JAMA 1983; 250: 1289-92.
233. Sumner D, Lambeth D. Reliability of Doppler ultrasound in the diagnosis of acute venous thrombosis both above and below the knee. Am J Surg 1979; 138: 205-10.
234. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
235. Tait RC, Walker ID, Islam SI, McCall F, Conkie JA, Mitchell R, Davidson JF. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993; 84: 476-80.
236. Tanis BC, Rosendaal FR, Koster T, Vandenbroucke. Combined effect of immobilisation and haemostatic risk factors on deep venous thrombosis. Thromb Haemostas 1997; 77 Suppl: 181.
237. The Columbus investigators. Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism. N Engl J Med 1997; 337: 657-62.
238. Thery C, Simonneau G, Meyer G, Helenon O, Bridey F, Armagnac C, d'Azemar P, Coquart JP. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparin) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation 1992; 85: 1380-90.
239. Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 335: 108-14.
240. Topol EJ, Fuster V, Harrinton RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK. Tannenbaum MA et al.. Recombinant Hirudin for unstable Angina Pectoris. A multicenler. randomized angiographic Trial. Circulation 1994; 89: 1557-66.
241. Torngren S, Hjertberg R, Rosfors S, Bremme K, Eriksson M, Swedenborg J. The long-term outcome of proximal vein thrombosis during pregnancy is not improved by the addition of surgical thrombectomy to anticoagulant treatment. Eur J Vasc Endovasc Surg 1996; 12: 31.
242. Trousseau A. Phlegmasia alba dolens. in: Lectures on clinical medicine, delivered at the Hotel-Dieu. Paris. A. Trousseau (eds). London: New Sydenham Society 1872; 281-95.
243. van der Meer FJM, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemostas 1997; 78: 631-5.
244. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oralanticontraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
245. Vila P, Hemandez MC. Lopez Fernaadez MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72: 209-13.
246. von der Lieth H. Chirurgische Behandlung der akuten Phlebothrombose. In: Gefaß krankheiten. Alexander K. (eds). München. Wien, Baltimore: Urban & Schwarzenberg 1992; 665-87.
247. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
248. Weber H, Loeprccht H, Venöse Thrombektomie. Indikation. Technik. Ergebnisse. Lanaenbecks Arch Chir 1988: Suppl 2: 169-75.
249. Weitz, JI, Drug therapy: Low-molecularweight heparins. N Engl J Med 1997; 337: 688-98.
250. Wells PS. Accuracy of clinical assessment of deep-vein thrombosis. Persönliche Mitteilung 1997.
251. Wells PS, Hirsh J, Anderson DR, Lensing AW, Foster G, Kearon C, Weitz J, D'Ovidio R, Cogo A, Prandoni P et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet 1995; 345: 1326-1330.
252. Wells PS, Brill-Edwards P, Stevens P, Panju A, Patel A, Douketis J, Massicotte MP, Hirsh J, Weitz JT et al.. A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. Circulation 1995; 91: 2184-7.
253. Wells PS, Hirsh J, Anderson DR, Lensing AW, Foster G, Kearon C, Weitz J, Cogo A, Prandoni P, Minuk T et al.. Comparison of the accuracy of impedance plethysmography and compression ultrasonography in outpatients with clinically suspected deep vein thrombosis. A two centre paired-design prospective trial. Thromb Haemostas 1995; 74: 1423.
254. Wheeler HB. Diagnosis of deep vein thrombosis. Review of clinical evaluation and impedance plethysmography. Am J Surg 1985: 150 Suppl: 7-11.
255. Wienert V, al. Welches Druckverhalten haben Antithrombosestrumpfe? Vasomed 1995;7:470-7.
256. Woolf SH. Current concepts: screening for prostate cancer with prostate-specific antigen - an examination of the evidence. N Engl J Med 1995; 333: 1401-5.
257. World Health Organisation collaborative study of cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-8.
258. Young E, Cosmi B, Weitz J.L, Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemostas 1993; 70: 625-30.
259. Zilliakus H.. On the specific treatment of thrombosis and pulmonary embolism, with special reference to the postthrombotic sequelae. Acta Med Scand 1946; Suppl 71: 171.
260. Zwaan M, Kagel Ch. Manenhoff N. Weiss HD, Grimm W, Eberhard I. Schwieder G. Erste Erfahrungen mit temporaren Venacava-Filtern. Röfo 1995; 163: 171-6.